Nelfinavir - A review of its therapeutic efficacy in HIV infection
Nelfinavir - A review of its therapeutic efficacy in HIV infection
复制标题
DOI：
10.2165/00003495-199856010-00013
复制
发表时间：
1998-07-01
期刊：
影响因子：
11.5
通讯作者：
Faulds, D
中科院分区：
文献类型：
--
作者：
Jarvis, B;Faulds, D
奈非那韦是HIV蛋白酶的选择性抑制剂，HIV蛋白酶负责HIV前肽的翻译后加工。在药物存在下，产生不成熟的非感染性病毒颗粒，奈非那韦与核苷逆转录酶抑制剂（NRTI）、非核苷逆转录酶抑制剂和/或其他蛋白酶抑制剂联合使用可显著抑制病毒复制。在大多数患者中，血浆HIV RNA水平（病毒水平）迅速降至检测限（LOD：通常为400或500拷贝/ml）以下。当与NRTI联合使用时，奈非那韦1250 mg每日两次在一系列每日总剂量下产生与每日3次奈非那韦相似的结果。在一项正在进行的研究中，>70%接受以奈非那韦为基础的联合治疗方案的成人血浆HIV RNA水平低于LOD（
Nelfinavir is a selective inhibitor of HIV protease, the enzyme responsible for post-translational processing of HIV propeptides. In the presence of the drug, immature, noninfectious virus particles are produced,Nelfinavir in combination with nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors and/or other protease inhibitors profoundly suppresses viral replication. Plasma HIV RNA levels (viral lend) rapidly fall below the limit of detection (LOD: usually 400 or 500 copies/ml) in the majority of patients. When used in combination with NRTIs, nelfinavir 1250 mg twice daily produced similar results to 3-times-daily nelfinavir at a range of total daily dosages. In an ongoing study >70% of adults receiving a nelfinavir-based combination regimen had plasma HIV RNA levels below the LOD (